3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
Sarcoma
1
Lymphoid
1
Conditions
Sarcoma, Synovial
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Osteosarcoma
2
Stomach Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Multiple Myeloma
1
Mesothelioma
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Temozolomide
128
Radiotherapy
85
Bevacizumab
43
Radiation
30
Carmustine
29
Irinotecan
25
Erlotinib Hydrochloride
22
Magnetic Resonance Spectroscopy
21
Chemotherapy, Adjuvant
20
Surgical Procedures, Operative
15
O(6)-benzylguanine
15
Carboplatin
14
sargramostim
12
Radiotherapy, Intensity-Modulated
12
Radiotherapy, Conformal
12
Sirolimus
10
Imatinib Mesylate
9
Filgrastim
9
Drug Therapy
9
temsirolimus
8
pembrolizumab
8
Thalidomide
8
Sorafenib
8
Radiosurgery
8
Gefitinib
8
motexafin gadolinium
7
aldesleukin
7
Procarbazine
7
Gene Expression Profiling
7
Cyclophosphamide
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
Immunotherapy, Adoptive
×
Sarcoma
×
Clear all
NCT02664363
2023-02-17
ExCeL
Duke University
Phase 1
Terminated
3 enrolled
8 charts